Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line Sunitinib

Pfizer

Status: Completed

Conditions: Metastatic Renal Cell Carcinoma

Treatments: Drug: Sunitinib

Study type: Observational

Funder types: Industry; Other

Identifiers

NCT04076787

A6181229

Details and patient eligibility

About

This is a retrospective, longitudinal cohort study that assessed clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) who received sunitinib as first-line treatment.

Full description

Clear cell mRCC patients who initiated sunitinib as first-line treatment between 2010 and 2018 were identified from the IMDC database. Patients were classified as favorable, intermediate, or poor prognostic risk group according to IMDC criteria. Overall survival, time to treatment discontinuation, and physician-assessed tumor response were evaluated.

Enrollment: 1,769 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosed with mRCC
• Initiated treatment post mRCC diagnosis and received sunitinib as first-line therapy
• Age 18 years or over at the time of mRCC diagnosis
• Actively treated at an IMDC clinical center

Exclusion criteria

• Initiated first line sunitinib treatment before 2010
• Had non-clear cell mRCC

Trial design

1,769 participants in 3 patient groups

Favorable IMDC risk group

Description:

The cohort of mRCC patients receiving sunitinib as first-line treatment and classified as favorable IMDC risk group for having 0 individual risk factor

Treatment:

Drug: Sunitinib

Intermediate IMDC risk group

Description:

The cohort of mRCC patients receiving sunitinib as first-line treatment and classified as intermediate IMDC risk group for having 1 or 2 individual risk factors

Treatment:

Drug: Sunitinib

Poor IMDC risk group

Description:

The cohort of mRCC patients receiving sunitinib as first-line treatment and classified as poor IMDC risk group for having 3 or more individual risk factors

Treatment:

Drug: Sunitinib